Objective hyperemia and intraocular pressure changes following omidenepag isopropyl application

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Conjunctival hyperemia is a common adverse reaction to omidenepag isopropyl ophthalmic solution.
• Omidenepag isopropyl is a selective E-prostanoid receptor-2 receptor agonist used for glaucoma treatment.

Purpose of the Study:

• To prospectively evaluate changes in conjunctival hyperemia and intraocular pressure (IOP) after initiating omidenepag isopropyl.
• To compare the effects of omidenepag isopropyl with previous prostaglandin analog treatments in glaucoma patients.

Main Methods:

• Prospective study involving glaucoma patients initiating omidenepag isopropyl.
• Hyperemia analysis software used to quantify vessel coverage from anterior segment images.
• Comparison of hyperemia and IOP before and after treatment initiation or drug switch.

Main Results:

• No significant change in hyperemia when switching from prostaglandin analogs to omidenepag isopropyl.
• Significant increase in hyperemia in new users of omidenepag isopropyl.
• Significant IOP reduction in new users, comparable to prostaglandin analogs.
• One case of spontaneous resolution of macular edema after discontinuing omidenepag isopropyl.

Conclusions:

• Omidenepag isopropyl demonstrates comparable IOP-lowering efficacy to prostaglandin analogs.
• New initiation of omidenepag isopropyl may lead to increased conjunctival hyperemia.
• The drug is generally well-tolerated, with potential for mild adverse effects like hyperemia.